Invest in ShockWave Medical Inc. (SWAV) to keep your portfolio healthy

The price of ShockWave Medical Inc. (NASDAQ: SWAV) closed at $264.06 in the last session, up 4.70% from day before closing price of $252.21. In other words, the price has increased by $+11.85 from its previous closing price. On the day, 458580 shares were traded. SWAV stock price reached its highest trading level at $268.31 during the session, while it also had its lowest trading level at $250.69.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



We take a closer look at SWAV’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 37.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 136.95. For the most recent quarter (mrq), Quick Ratio is recorded 6.00 and its Current Ratio is at 7.30. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.

Upgrades & Downgrades

On April 06, 2022, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $255.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 21 when PUCKETT DAN sold 1,100 shares for $246.96 per share. The transaction valued at 271,656 led to the insider holds 39,938 shares of the business.

WATKINS FRANK T sold 3,000 shares of SWAV for $733,323 on Nov 17. The Director now owns 3,796 shares after completing the transaction at $244.44 per share. On Nov 14, another insider, Godshall Douglas Evan, who serves as the President & CEO of the company, sold 30,000 shares for $240.81 each. As a result, the insider received 7,224,301 and left with 82,926 shares of the company.

Valuation Measures:

As of this moment, ShockWave’s Price-to-Earnings (P/E) ratio for their current fiscal year is 112.22, and their Forward P/E ratio for the next fiscal year is 70.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.04 while its Price-to-Book (P/B) ratio in mrq is 26.70.

Stock Price History:

Over the past 52 weeks, SWAV has reached a high of $320.54, while it has fallen to a 52-week low of $113.36. The 50-Day Moving Average of the stock is 271.37, while the 200-Day Moving Average is calculated to be 217.36.

Shares Statistics:

According to the various share statistics, SWAV traded on average about 487.07K shares per day over the past 3-months and 476.86k shares per day over the past 10 days. A total of 36.00M shares are outstanding, with a floating share count of 35.75M. Insiders hold about 1.60% of the company’s shares, while institutions hold 92.50% stake in the company. Shares short for SWAV as of Oct 13, 2022 were 1.67M with a Short Ratio of 1.49M, compared to 1.76M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.65% and a Short% of Float of 4.71%.

Earnings Estimates

The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.67 for the current quarter, with a high estimate of $0.8 and a low estimate of $0.5, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.81, with high estimates of $1.07 and low estimates of $0.6.

Analysts are recommending an EPS of between $2.94 and $2.16 for the fiscal current year, implying an average EPS of $2.55. EPS for the following year is $3.51, with 7 analysts recommending between $4.3 and $2.46.

Revenue Estimates

According to 6 analysts, the current quarter’s revenue is expected to be $123.97M. It ranges from a high estimate of $130.04M to a low estimate of $121.8M. As of the current estimate, ShockWave Medical Inc.’s year-ago sales were $65.16M, an estimated increase of 90.30% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $137.85M, an increase of 63.80% less than the figure of $90.30% in the same quarter last year. There is a high estimate of $150.03M for the next quarter, whereas the lowest estimate is $132.85M.

A total of 7 analysts have provided revenue estimates for SWAV’s current fiscal year. The highest revenue estimate was $494.45M, while the lowest revenue estimate was $470M, resulting in an average revenue estimate of $475.94M. In the same quarter a year ago, actual revenue was $237.15M, up 100.70% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $618.62M in the next fiscal year. The high estimate is $625.3M and the low estimate is $606M. The average revenue growth estimate for next year is up 30.00% from the average revenue estimate for this year.